PPT-Neurotransmitter-coumarin derivatives as potential SARS-CoV-2 main protease inhibitors
Author : CutiePie | Published Date : 2022-08-03
Dejan Milenković 1 Dušan Dimić 2 Edina Avdović 1 Jelena Đorović Jovanovi ć 1 Žiko Milanović 3 Marko Antonijević 1 Jasmina DimitrićMarković
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Neurotransmitter-coumarin derivatives as..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Neurotransmitter-coumarin derivatives as potential SARS-CoV-2 main protease inhibitors: Transcript
Dejan Milenković 1 Dušan Dimić 2 Edina Avdović 1 Jelena Đorović Jovanovi ć 1 Žiko Milanović 3 Marko Antonijević 1 Jasmina DimitrićMarković. Bombyx mori. Present by . Mr.M.Kannan, M.Sc., PGDEG,. Research Scholar . Under the guidance of . Prof. . M.Krishnan . Insect Molecular Biology laboratory. Department of Environmental Biotechnology. Bharathidasan University, Tiruchirappalli-620 024. Page 9 Yan Leyfman 1 , Timothy K. Erick 1 , Pushpa Sharma 1,2 1 WACEM-ACAIM Joint Global COVID-19 Taskforce Immunology Division, USA 2 Department of Anaesthesiology, Uniformed Services Universit 1 1. You have published many papers on coronaviruses and even warned of the possibility of a serious spillover event from animals to humans. Do you feel like your warnings were not appropriately hee J E Rodrguez ChanfrauFacultad de Qumica Uni-versidad de la HabanaCiudad de la HabanaCP 10600 Cuba E-mail jerodriguezfquhcuArticleBrazilian Journal of Pharmaceutical Sciencesvol 51 n 1 jan/mar 2015http One Health Partners Monthly COVID-19 WebinarCoordinated by the CDCOne Health Office in partnership with the One Health Federal Interagency COVID-19 Coordination OH-FICC GroupOne May 27. 2020. K.Dharmalingam. Asymptomatic Likely but remote. Prodromal Yes. Oligosymptomatic Yes. Polysymptomatic Yes. Spread occurs from all these groups of patients. Fauci. , for one, still believes it does.. Analytical & Clinical Performance Data (OUS). June 2020. HOOD05162003091712. FTD SARS-CoV-2 Assay*. Instructions for Use. *. CE-IVD labelled for diagnostic use in the EU. . The . Instructions for Use . David J. Weber, MD, MPH, FIDSA, FSHEA, FRSM (London). Sanders Distinguished Professor of Medicine, Pediatrics and Epidemiology. Associate Chief Medical Officer. Medical Director, Hospital Epidemiology. 1,2,3. *. , . Sarah Temmam. 4. *,. . Christèle. Huon. 4. , Sylvie Behillil. 5,6. , Vincent Gajdos. 7,8, . Thomas Bigo. t4,9. , Thibaut Lurier. 10,11,12. , Delphine Chrétien. 4. , . Marija. Backovic. A drug repurposing approach for COVID-19. Md. Riad Chowdhury. 1. , . Md. . Adnan. 2,*. , . Md. Nazim Uddin . Chy. 1,*. , . A.T.M. Mostafa Kamal. 1. 1. Department of Pharmacy, International Islamic University Chittagong, . Dina. saleem. Coumarin. The interaction between . salicyldehyde. . and acetic anhydride in the presence of sodium acetate results into the formation of the heterocyclic . pyran. ring to give . coumarin. Department Medicine. UF College of Medicine. Randomized trial of bicalutamide to block . TMPRSS2 in males with COVID-19 infection. UF-CTSI Pilot grant project. Association between . Cancer and COVID-19 Biology. Also Called . 3CL Proteinase. Collaborative Curriculum Development Program 2020. What does SARS-CoV-2 look like? . Severe acute Respiratory Syndrome -Coronavirus-2. Large (~30Kb) . +RNA genome. . https://viralzone.expasy.org/764?outline=all_by_species. (virus). Guam Department of Public Health and Social Services. Disclaimer: This is a rapidly evolving situation. Information and guidance are constantly changing. Information presented in these slides may already be out-of-date..
Download Document
Here is the link to download the presentation.
"Neurotransmitter-coumarin derivatives as potential SARS-CoV-2 main protease inhibitors"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents